References of "NYSSEN, Astrid"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailLe cas clinique du mois. Péricardite purulente chez un patient atteint de sarcoïdose pulmonaire
NYSSEN, Astrid ULg; MELON, Pierre ULg; GARWEG, Christophe ULg et al

in Revue Médicale de Liège (2011)

We report the case of a patient, suffering from pulmonary sarcoidosis, who developed a purulent pericarditis complicated with a cardiac tamponade. The widespread use of antibiotics has progressively ... [more ▼]

We report the case of a patient, suffering from pulmonary sarcoidosis, who developed a purulent pericarditis complicated with a cardiac tamponade. The widespread use of antibiotics has progressively reduced the number of purulent pericarditis. However, it remains a serious disease that has to be rapidly diagnosed to be treated timely. We will review the required tests for the diagnosis and the treatment of this pathology that leads to death otherwise. The link with pulmonary sardoidosis is uncertain. [less ▲]

Detailed reference viewed: 41 (7 ULg)
Full Text
Peer Reviewed
See detailRapport benefice/risque des endoprotheses coronaires pharmaco-actives. 2ème partie : analyse dans la population diabétique
Nyssen, Astrid ULg; Legrand, Victor ULg; Scheen, André ULg

in Revue Médicale de Liège (2008), 63(11), 654-661

The diabetic patient is at high risk of coronary heart disease. He/she can benefit of revascularisation procedures, even if he/she is exposed to a higher incidence of complications after a coronary artery ... [more ▼]

The diabetic patient is at high risk of coronary heart disease. He/she can benefit of revascularisation procedures, even if he/she is exposed to a higher incidence of complications after a coronary artery bypass graft or a percutaneous transluminal coronary angioplasty. The use of drug-eluting stents — paclitaxel (PES) or sirolimus (SES) — dramatically reduces the risk of restenosis as compared to bare-metal stents; nevertheless, the rate of restenosis remains almost double in diabetic patients compared to that observed in non-diabetic subjects. However, the risk of (very) late thrombosis is higher with drug-eluting stents than with bare-metal stents, in the diabetic population as in the non-diabetic population. Altogether, among diabetic patients, the incidence of major cardiovascular events is significantly reduced with drug-eluting stents. This global clinical benefit essentially results from a diminution of revascularisation procedures rather than from a reduction of myocardial infarcts or cardiovascular deaths. Comparison between SES and PES gives discordant results. Indeed, while the loss of intra-stent lumen is more important with PES than with SES, PES are associated with a lower rate of major cardiovascular events than SES. Efficacious antiplatelet therapy in the long run is mandatory in all diabetic patients treated with drug-eluting stents [less ▲]

Detailed reference viewed: 67 (4 ULg)
Full Text
Peer Reviewed
See detailRapport benefice/risque des endoprotheses coronaires pharmaco-actives. 1ere partie: analyse dans la population generale.
Nyssen, Astrid ULg; Legrand, Victor ULg; Scheen, André ULg

in Revue Médicale de Liège (2008), 63(9), 542-8

Coronary drug-eluting stents (DES) are increasingly used in interventional cardiology. Stents coated with pharmacological substances such as sirolimus or paclitaxel, capable of reducing endothelial ... [more ▼]

Coronary drug-eluting stents (DES) are increasingly used in interventional cardiology. Stents coated with pharmacological substances such as sirolimus or paclitaxel, capable of reducing endothelial proliferation, have been proposed to replace bare-metal stents (BMS) in order to reduce the risk of restenosis. The survey of the literature confirms a major and significant reduction in the risk of restenosis with both sirolimus and paclitaxel DES as compared to BMS in the global population. This effect leads to a diminished requirement for new revascularisation procedures. However, such DES may increase the risk of very late stent thrombosis, presumably due to a defect of endothelialisation, which requires long-term effective antiplatelet therapy. The impact on major clinical coronary events shows no significant difference in mortality between DES and BMS. However, the incidence of myocardial infarct may be, slightly but significantly, reduced with sirolimus DES. In a next paper, the same analysis will be specifically performed in the diabetic population, which is well known to be at high risk of coronary heart disease, but is also expected to particularly benefit from DES. [less ▲]

Detailed reference viewed: 80 (7 ULg)